<DOC>
	<DOC>NCT00190788</DOC>
	<brief_summary>The purpose of this study is to determine whether continued administration of Drotrecogin Alfa (Activated) up to additional 72 hours - after the so far recommended 96 hour infusion period - results in a more rapid resolution of hypotension in severe septic patients.</brief_summary>
	<brief_title>Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion</brief_title>
	<detailed_description />
	<mesh_term>Hypotension</mesh_term>
	<mesh_term>Drotrecogin alfa activated</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<criteria>Severe sepsis patients treated with 96 hour infusion of commercial Drotrecogin Alfa (Activated) Continue requirement of Vasopressor support after 96 hour commercial infusion Patients require extensive surgical procedures within next 3 days Patients with platelet count below 30,000/mm3 Patients receiving therapeutic heparin of 15,000 units/day and more Patients not expected to survive 24 days Patients contraindicated as to the country specific registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>